Rapid’s, FDA-cleared dosimetry software, 3D-RD-S, Receives CE Mark Approval, Expanding Global Access to Cutting-Edge Radiopharmaceutical Dosimetry Software

Baltimore, Maryland, – Rapid®, a trailblazer in quantitative imaging and dosimetry solutions, is proud to announce the approval of the CE mark for its dosimetry software, 3D-RD-S. This significant achievement marks a major milestone in the company’s mission to transform radiopharmaceutical dosimetry for a global audience. 


CE marking, a mandatory conformity marking for products sold within the European Economic Area (EEA), confirms that 3D-RD-S meets all stringent requirements of the EU Medical Device Regulation (EU MDR). This marking signifies the product’s compliance with European health, safety, and environmental protection standards. With this approval in place, Rapid is empowered to extend the reach of its groundbreaking software, enhancing the precision and efficiency of radiopharmaceutical dosimetry for medical professionals across the EEA.


3D-RD-S: Elevating Radiopharmaceutical Dosimetry to New Heights

3D-RD-S is a web-based software application designed to make radiopharmaceutical dosimetry easy. The software features one of the most powerful time-activity-curve fitting and integration algorithms, and the ability to allocate daughter decays from alpha-particle emitting parents such as Ac-225. It is delivered via a web link and executes through a web browser. It offers multi-user, multi-project functionality that is ideal for multi-center clinical trials or for expert review of calculations. It provides comprehensive reporting output whereby all, including, the decay scheme and S-value used in a calculation are included. It also provides a tracking feature to support enterprise-wide QC/QA functionality. Its advanced algorithms, user-friendly interface, and regulatory-ready reporting capabilities position 3D-RD-S as a transformative tool in dosimetry workflows.


Global Accessibility and Impact

The CE mark amplifies Rapid’s commitment to advancing healthcare solutions that align with the highest quality standards. With 3D-RD-S now bearing the CE mark, the software is accessible to medical professionals, researchers, and institutions within the EEA. This milestone solidifies Rapid’s dedication to facilitating more informed decisions, efficient dosimetry processes, and improved patient outcomes on a global scale.


A Message from Rapid’s Leadership

We are thrilled to announce the CE mark approval for 3D-RD-S, a testament to our unwavering commitment to excellence in dosimetry solutions. This achievement underscores our dedication to empowering dosimetry across the EEA with a state-of-the-art tool that enhances their ability to optimize the dosimetry processes. We look forward to the positive impact this approval will have on future patient care, research, and innovation.”


Experience the Future of Radiopharmaceutical Dosimetry

For professionals and institutions seeking to harness the innovative power of 3D-RD-S, Rapid invites you to explore the software’s capabilities and potential. To learn more, request a demonstration, or inquire about integration opportunities, please email sales@rapiddosimetry.com.


About Rapid: 

Rapid’s mission is to help make cancer curable by providing simplified, accurate and standardized dosimetry that enables routine precision dosing of RPT. Rapid brings more than 90 years of experience in the fields of quantitative imaging and dosimetry to market. Rapid is advancing the standards of dosimetry in radiopharmaceutical therapy (RPT). Rapid provides comprehensive expert services and software solutions related to quantitative imaging, and dosimetry, in support of pre-clinical and clinical studies needed for regulatory approval and for the effective and safe clinical implementation of radiopharmaceuticals.

3D-RD-S was designed and developed with support from a loan from the Maryland Technology Development Corporation and by the National Cancer Institute of the National Institutes of Health under award numbers R43CA224643R43-CA213782, and R44-CA213782. The product is solely the responsibility of Rapid and does not represent the official views of the National Institutes of Health.


For media inquiries, please contact:

Michael Ghaly, Ph.D.

CTO and Co-Founder